Abstract
Invasive meningococcal disease (IMD) is a severe and unpredictable disease, causing acute meningitis and sepsis, which are associated with high mortality and long-term consequences. A national immunization programme to prevent IMD caused by meningococcal serogroups A, C, W and Y has been introduced in the Netherlands. This study aimed to estimate the incremental cost-effectiveness ratio (ICER) of introducing the protein-subunit-meningococcal-B-vaccine (4CMenB) to prevent IMD caused by Meningococcal B by using a dynamic transmission-based cost-effectiveness (DyCE) model.
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
